metaEvidence - overview


			deaths (OS)
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus Ipilimumab (10 mg/kg)
	nivolumab alone vs. Ipilimumab (10 mg/kg)	1	0.87 [0.66; 1.14], 1 RCT, I2=0% inconclusive result
versus placebo
	nivolumab alone vs. placebo	1	-
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab alone vs. ipilimumab alone	1	0.63 [0.48; 0.82], 1 RCT, I2=0% conclusive unassessable degree of certainty
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus dacarbazine
	nivolumab alone vs. dacarbazine	1	0.42 [0.25; 0.72], 1 RCT, I2=0% conclusive unassessable degree of certainty
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus Standard of Care (SoC)
	nivolumab alone vs. Standard of Care (SoC)	1	0.95 [0.73; 1.24], 1 RCT, I2=0% inconclusive result
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant